Recent Finacing
Recent Raise
Endevica Bio develops patent-protected modified-peptide therapeutics that target GPCRs behind the blood–brain barrier, advancing TCMCB07, an MC3/4 antagonist, through Phase 1 SAD/MAD clinical testing for cachexia.
Focus Areas
Total Raised
Funding round
See the team members at Endevica Bio.
